Clinical pathology labs take note: Death march for fee-for-service payment model continues as support for change gathers steam Dark Daily
Today there is wide recognition in healthcare that the days of fee-for-service medicine are numbered. But what is less certain is how fast government and private payers will introduce other reimbursement models, such as bundled payments and budgeted payments. Clinical laboratories and anatomic pathology groups likely will be the most impacted by this payment shift since their economics are driven by high volumes and FFS payment.
Read Florida Society of Pathologists comment to First Coast Service Options on the draft Local Coverage Determination: Special Histochemical Stains and Immunohistochemical Stains (DL36324)
Dear Dr. Corcoran and Dr. Polsky,
The Florida Society of Pathologists (FSP), representing more than 350 pathologists in the state of Florida, appreciates this opportunity to comment on the draft Local Coverage Determination: Special Histochemical Stains and Immunohistochemical Stains (DL36324).
Our Florida medicare service provider, First Coast Service Options, has a draft local coverage determination submitted for public comment by July 27, 2015. This dLCD essentially mirrors the restrictive Palmetto LCD that was approved earlier for that service area. This broad dLCD covers a wide range of pathology anatomic services including breast, GI, GU, lung and skin. Your FSP has been actively interacting with FCSO and with the CAP and is requesting changes to this dLCD.
Sizeable deductibles cause patients to owe more money to clinical pathology labs, spurring labs to get smarter about collecting Dark Daily
In today's clinical laboratory marketplace, competency in revenue management is becoming just as important as clinical excellence. Blame it on these multi-year trends: shrinking lab budgets, Medicare price cuts, and payers excluding labs from narrow networks. At the dawn of this decade — just five years ago — few pathologists and clinical lab executives would have predicted that the financial survival of their lab organizations would depend upon becoming more proficient and more sophisticated with billing and collections.
NIH's drug lab is shut down after FDA finds quality failures Bloomberg
A U.S.-run laboratory that makes drugs for the National Institutes of Health's clinical trials failed a government quality inspection and will be temporarily shut down. The U.S. Food and Drug Administration, the government regulator that spends much of its time making sure drug companies follow exacting quality standards, inspected the NIH's Pharmaceutical Development Section. The lab makes drugs that are used in government-sponsored clinical trials at the NIH hospital in Bethesda, Maryland. Operations at the lab have been suspended.
Has the time come for integration of radiology and pathology? Dark Daily
For years, certain pathologists and radiologists have floated the idea that an integrated diagnostic service involving both medical specialties could improve patient safety and contribute to improved patient outcomes. Now that the U.S. healthcare system is encouraging tighter integration of clinical services, advocates of an integrated diagnostic service involving radiology and pathology believe that the era of integrated diagnostics may be soon upon us.
Florida State Legislative Session Recap FSP
As of April 28, 2015, the Florida Legislature adjourned sine die in a historic way. Due to a bitter impasse between House Republicans and the Senate over Medicaid expansion, the House packed up their bags and went home three days early before the official May 1 adjournment. This was an unprecedented and historic end to a contentious session. As a result of the surprise shut-down, every piece of legislation relating to healthcare, with the exception of a clinical laboratory bill that we amended and supported (see SB 738), failed passage. We worked hard on so many issues for over six months including prohibition against balance billing, a potential fix to the Beacon/United issue, telemedicine, prohibiting reimbursement tied to a Medicare standard, and many others.
6 hours of sleep: Is it enough for some patients? Medscape
Obtaining sufficient sleep is a crucial component of proper health maintenance. Some authors have gone so far as to recommend that sleep be considered an additional "vital sign" to be assessed at each healthcare provider visit. There are multiple facets to a comprehensive sleep evaluation for an individual patient; however, one of the most important measures is average sleep duration each night. Although all might agree on the importance of total sleep time, it isn't clear what the nightly target should be. In other words, how much sleep is enough for your patient? Before providing an answer to this surprisingly complex question, it's worth taking the time to review the science of health outcomes as they relate to sleep.
2 American diagnostics labs get hit with a $48.5 million fine for providing unnecessary medical tests The Standard Daily
Two U.S. companies have been slammed with a joint $48.5 million fine for conducting unnecessary medical tests in affinity with doctors that refer patients to them for a commission. The companies are Health Diagnostics Laboratory (HDL) and Singulex, two cardiovascular disease testing labs. HDL is fined the sum of $47 and Singulex is to pay back $1.5 million; but then, neither of the companies admitted any guilt or liability in the lawsuit brought against them.
CAP response: JAMA breast biopsy study College of American Pathologists
On March 17, the Journal of the American Medical Association published a study, "Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens," which examined pathologists' interpretations of breast biopsies. As the world's largest organization of board-certified pathologists, the CAP believes this article may lead to unnecessary worry for patients.